(Q44880533)

7 December 2017

title

Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects (English)

1 reference

7 December 2017

0 references

1 reference

1 reference

3

Karl O Nakken

1 reference

7 December 2017

Eylert Brodtkorb

1

1 reference

7 December 2017

Theresa M Klees

series ordinal

2

1 reference

7 December 2017

Rasmus Lossius

series ordinal

4

1 reference

7 December 2017

Svein I Johannessen

series ordinal

5

1 reference

7 December 2017

publication date

1 April 2004

1 reference

7 December 2017

1 reference

7 December 2017

volume

5

1 reference

7 December 2017

issue

2

1 reference

7 December 2017

page(s)

231-235

1 reference

Prevalence of epilepsy in adults in northern Sweden

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

Behavioral assessment in mentally retarded and developmentally disabled patients with epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

Efficacy of levetiracetam in developmentally disabled patients: a review of the literature and six case reports

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

Efficacy of levetiracetam: a review of three pivotal clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

Antiepileptic drugs as a cause of worsening seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

Seizure-inducing effects of antiepileptic drugs: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

A systematic review of the safety profile of levetiracetam: a new antiepileptic drug.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

Behavioural effects of the new anticonvulsants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

Levetiracetam psychosis in children with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

Psychiatric adverse events during levetiracetam therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

Levetiracetam in autistic children: an open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.12.005

10.1016/J.YEBEH.2003.12.005

7 January 2021

Identifiers

DOI

1 reference

7 December 2017

1 reference